TSHA Stock Overview
A gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Taysha Gene Therapies, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.01 |
52 Week High | US$4.32 |
52 Week Low | US$1.27 |
Beta | 0.39 |
11 Month Change | -6.94% |
3 Month Change | -7.16% |
1 Year Change | -32.32% |
33 Year Change | -89.50% |
5 Year Change | n/a |
Change since IPO | -91.65% |
Recent News & Updates
Recent updates
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%
Jun 27Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky
Jun 20Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07Shareholder Returns
TSHA | US Biotechs | US Market | |
---|---|---|---|
7D | -6.5% | -3.8% | 1.8% |
1Y | -32.3% | 16.5% | 31.9% |
Return vs Industry: TSHA underperformed the US Biotechs industry which returned 18.7% over the past year.
Return vs Market: TSHA underperformed the US Market which returned 32.8% over the past year.
Price Volatility
TSHA volatility | |
---|---|
TSHA Average Weekly Movement | 10.2% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TSHA's share price has been volatile over the past 3 months.
Volatility Over Time: TSHA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2019 | 52 | Sean Nolan | www.tayshagtx.com |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center.
Taysha Gene Therapies, Inc. Fundamentals Summary
TSHA fundamental statistics | |
---|---|
Market cap | US$422.18m |
Earnings (TTM) | -US$114.33m |
Revenue (TTM) | US$12.87m |
32.0x
P/S Ratio-3.6x
P/E RatioIs TSHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TSHA income statement (TTM) | |
---|---|
Revenue | US$12.87m |
Cost of Revenue | US$0 |
Gross Profit | US$12.87m |
Other Expenses | US$127.21m |
Earnings | -US$114.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.56 |
Gross Margin | 100.00% |
Net Profit Margin | -888.18% |
Debt/Equity Ratio | 34.8% |
How did TSHA perform over the long term?
See historical performance and comparison